You are viewing: UK Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The UK Cancer Biomarkers Market was valued at $1391.7 Million in 2026 and projected to reach to $2965.1 Million by 2031, representing a compound annual growth rate of CAGR 13.4%. The UK cancer biomarkers market is positioned for sustained expansion through 2031, driven by NHS initiatives promoting early cancer detection and personalized treatment strategies.

UK Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Cancer Biomarkers Market Trends and Insights

  • The UK's advanced healthcare infrastructure and strong investment in precision oncology are driving adoption of biomarker-based diagnostics and therapeutics.
  • The UK's National Health Service commitment to personalized medicine and early cancer detection initiatives are accelerating demand for innovative biomarker solutions across the forecast period. The UK market benefits from a highly skilled workforce, substantial research funding, and established regulatory pathways that facilitate rapid commercialization of biomarker technologies.
  • UK-based pharmaceutical and diagnostics companies are leading innovation in liquid biopsy, genomic profiling, and immunotherapy biomarkers.
  • The UK's growing emphasis on value-based healthcare and outcomes-driven treatment strategies is positioning biomarkers as essential tools for treatment selection and patient stratification through 2031. With a compound annual growth rate of 13.4%, the UK cancer biomarkers market is outpacing global trends, reflecting the region's commitment to advancing oncology care.
  • The UK's regulatory environment and collaborative research ecosystem continue to attract investment and drive market expansion, making it a key hub for biomarker development and clinical implementation..

Key Market Statistics

  • CAGR (2026-2031) CAGR 13.4%
  • Market Size, 2026 ~USD 1391.7 Million
  • Forecast, 2031 ~USD 2965.1 Million
  • Country UK

UK Cancer Biomarkers Market Overview

Market Valuation Growth :

The UK cancer biomarkers market is valued at $1,391.7 million in 2026 and is projected to reach $2,965.1 million by 2031, representing a robust 13.4% CAGR over the forecast period.

NHS Precision Medicine Initiative :

The UK National Health Service's commitment to personalized medicine and early cancer detection is accelerating the adoption of biomarker-based diagnostics across NHS trusts and private healthcare providers.

Advanced Healthcare Infrastructure :

The UK's world-class healthcare system and substantial investment in precision oncology research are creating a favorable environment for biomarker innovation and clinical implementation.

Outpacing Global Growth :

The UK market's 13.4% CAGR significantly exceeds the global cancer biomarkers market growth rate of 11.6%, indicating accelerated adoption and market maturation in the region.

UK Cancer Biomarkers Market Dynamics

  • Increasing collaboration between academic institutions, pharmaceutical companies, and healthcare providers is fostering innovation in liquid biopsy technologies and genomic profiling.
  • The UK's regulatory framework and reimbursement policies are becoming increasingly supportive of biomarker-driven diagnostics, encouraging market entry and investment.
  • Healthcare providers are prioritizing precision oncology to improve patient outcomes and optimize treatment efficacy, creating strong demand for validated biomarker solutions across oncology centers and primary care settings..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • The UK cancer biomarkers market will grow from $1,391.7M in 2026 to $2,965.1M in 2031, representing a 13.4% CAGR.
      • The UK's NHS-backed precision medicine initiatives and early detection programs are primary growth catalysts for biomarker adoption.
      • The UK's regulatory environment and research infrastructure position it as a leading hub for biomarker innovation and commercialization.
      • The UK market is outpacing global growth rates, driven by strong investment in genomic profiling, liquid biopsy, and immunotherapy biomarkers.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      UK Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      UK: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS276.4307.6347.2393.3510.6586.7678.4785.214.6
      DIAGNOSTIC LABORATORIES652716.7798.68931129.512811461.71669.213.1
      OTHER END USERS48.751.755.760.270.877.384.893.18.9
      RESEARCH AND ACADEMIC INSTITUTES152.9169.4190.2214.4275.6315.1362.6417.614
      TOTAL11301245.51391.71560.91986.42260.12587.52965.113.4

      Target Audience

      • Pharmaceutical & Biotech Companies : UK-based and international pharma firms need market data to guide precision oncology product development, clinical trial planning, and commercialization strategies in the UK.
      • Diagnostic Laboratory Providers : Clinical laboratories and diagnostic service providers require UK market insights to assess demand for biomarker testing services and plan capacity expansion.
      • NHS Trust Leadership : Hospital administrators and oncology department heads need market intelligence to justify biomarker testing investments and align with NHS precision medicine initiatives.
      • Medical Device & IVD Manufacturers : In vitro diagnostics and medical device companies need UK-specific market data to evaluate opportunities for biomarker assay platforms and companion diagnostic tools.
      • Healthcare Investors & Consultants : Private equity firms, venture capitalists, and management consultants require detailed UK market analysis to identify investment opportunities and advise healthcare clients.

      Key Companies in the UK Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data for the UK market ($1,391.7M in 2026) with detailed forecasts through 2031, enabling accurate budget allocation and investment planning for UK operations.
      • NHS Integration Insights : Understand how NHS procurement policies, reimbursement frameworks, and personalized medicine initiatives are shaping biomarker adoption across UK healthcare systems.
      • Competitive Landscape Analysis : Identify key players, market consolidation trends, and competitive positioning specific to the UK market to inform go-to-market strategies and partnership opportunities.
      • Growth Driver Identification : Discover UK-specific factors driving the 13.4% CAGR, including regulatory changes, technology adoption rates, and healthcare provider investment priorities.
      • Strategic Decision Support : Leverage UK market intelligence to support product development, market entry decisions, and resource allocation for biomarker diagnostics and therapeutic companies.

      Frequently asked questions

      What is the current size of the UK cancer biomarkers market?

      The UK cancer biomarkers market is valued at $1,391.7 million in 2026 and is projected to reach $2,965.1 million by 2031.

      What is the growth rate of the UK cancer biomarkers market?

      The UK cancer biomarkers market is growing at a compound annual growth rate (CAGR) of 13.4% from 2026 to 2031.

      What are the main drivers of growth in the UK cancer biomarkers market?

      Key drivers include NHS precision medicine initiatives, early cancer detection programs, advanced regulatory pathways, and strong investment in genomic and immunotherapy biomarkers.

      How does the UK market compare to global cancer biomarkers growth?

      The UK's 13.4% CAGR outpaces the global average of 11.6%, reflecting the region's advanced healthcare infrastructure and commitment to personalized oncology.

      Which biomarker technologies are driving UK market expansion?

      Liquid biopsy, genomic profiling, and immunotherapy biomarkers are leading innovation and adoption across the UK healthcare system.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status